CYTISINE
- CAS No.
- 485-35-8
- Chemical Name:
- CYTISINE
- Synonyms
- Cytisinicline;Cytisin;SOPHORINE;(1R,5S)-1,2,3,4,5,6-Hexahydro-8H-1,5-methanopyrido[1,2-a][1,5]diazocin-8-one;Tabax;Ulexin;(-)-CYTISINE;(-)-Cytisine;Cytisine,()-Cytisine, (1R,5S)-1,2,3,4,5,6-Hexahydro-1,5-methano-8H-pyrido[1,2a][1,5]diazocin-8-one, (1S,9S)-3,11-Diazatricyclo[7.3.1.03,8]trideca-5,7-dien-4-one;Tabex
- CBNumber:
- CB1136805
- Molecular Formula:
- C11H14N2O
- Molecular Weight:
- 190.24
- MOL File:
- 485-35-8.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/7/25 20:04:51
| Melting point | 154-156 °C (lit.) |
|---|---|
| Boiling point | 218 °C/2 mmHg (lit.) |
| alpha | D17 -120° |
| Density | 1.0815 (rough estimate) |
| refractive index | 1.5700 (estimate) |
| storage temp. | Keep in dark place,Sealed in dry,2-8°C |
| solubility | 439g/l |
| pka | 6.11, 13.08(at 25℃) |
| form | powder |
| color | light yellow |
| optical activity | [α]/D -108±3°, c = 1% in ethanol |
| Water Solubility | 439g/L(16 ºC) |
| Merck | 14,2789 |
| InChIKey | ANJTVLIZGCUXLD-DTWKUNHWSA-N |
| LogP | 0.172 (est) |
| CAS DataBase Reference | 485-35-8 |
| NIST Chemistry Reference | Cytisine(485-35-8) |
| EPA Substance Registry System | Cytisine (485-35-8) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS06 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H301+H311+H331 | |||||||||
| Precautionary statements | P261-P264-P280-P301+P310-P302+P352+P312-P304+P340+P311 | |||||||||
| Hazard Codes | T | |||||||||
| Risk Statements | 25-36/37/38 | |||||||||
| Safety Statements | 26-28-36/37-45 | |||||||||
| RIDADR | UN 2811 6.1/PG 3 | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | HA4025000 | |||||||||
| HazardClass | 6.1(b) | |||||||||
| PackingGroup | III | |||||||||
| HS Code | 29399990 | |||||||||
| Toxicity | LD50 in mice (mg/kg): 1.73 i.v.; 9.4 i.p.; 101 orally (Barlow, McLeod) | |||||||||
| NFPA 704 |
|
CYTISINE price More Price(11)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | C2899 | Cytisine ≥99%, powder | 485-35-8 | 5MG | ₹7523.38 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | C2899 | Cytisine ≥99%, powder | 485-35-8 | 25MG | ₹27430.55 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | C2899 | Cytisine ≥99%, powder | 485-35-8 | 100MG | ₹77734.33 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | C2899 | Cytisine ≥99%, powder | 485-35-8 | 250MG | ₹156204.75 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | 712264 | Cytisine ≥99.0% (HPLC), ≥99% | 485-35-8 | 100MG | ₹13390.53 | 2022-06-14 | Buy |
CYTISINE Chemical Properties,Uses,Production
Chemical Properties
Off-White to Tan Crystalline Solid
Physical properties
Appearance: white or yellow powder. Solubility: soluble in water, pyridine, acetone, ethanol, and methanol and only slightly soluble in benzene but insoluble in petroleum ether. Melting point: 154–156?°C. Specific optical rotation: ?114.0 to ?116.0° (C?=?0.1, H2O). Toxic, stable under room temperature, and should be kept in a dry and dark place.
Uses
Cytisine occurs in the seeds of Cytisus labur num L. and other Leguminosae.
Indications
It is the first effective medicine in the world for smoking cessation, which does not contain nicotine and antidepressants. It is administered perorally according to the following schedule:
First 3 days: one tablet six times daily (every 2 h) with a parallel reduction of the
number of cigarettes smoked.
If the result is unsatisfactory, the treatment is discontinued, and a new therapy
can be resumed after 2–3 months. In case of good effect, the treatment should continue according to the following schedule:
Fourth to 12th day: one tablet every 2 and 1/2 h (five tablets daily)
Thirteenth to 16th day: one tablet every 3 h (four tablets daily)
Seventeenth to 20th day: one tablet every 5 h (three tablets daily)
Twenty-first to 25th day: one to two tablets daily
Definition
ChEBI: An organic heterotricyclic compound that is the toxic principle in Laburnum seeds and is found in many members of the Fabaceae (legume, pea or bean) family. An acetylcholine agonist, it is widely used throughout Eastern Europe as n aid to giving up smoking.
General Description
Cystine ((1R,5S)-1,2,3,4,5,6-hexahydro-1,5-methano-8H-pyrido[1,2a][1,5]diazocin-8-one) displays classical antidepressant action in various animal models of antidepressant efficacy. Infrared and Raman spectral studies suggest that it has two stable conformers.
Health Hazard
Cytisine is highly toxic to humans and ani mals. Ingestions may cause nausea, vomiting,and convulsions. Death may occur from respiratory failure
LD50 value, oral (rats): 101 mg/kg.
Biological Activity
A potent, selective agonist at neuronal nicotinic receptors. Acts as a partial agonist at β 2-containing nicotinic receptors.
Pharmacology
Tobacco smoking is one of the main threats to human health. Nicotine is responsible for the dependence of tobacco, and it is commonly accepted that nicotine addiction results from its interaction with neuronal nicotinic acetylcholine receptors (nAChRs). Cytisine has a similar chemical structure to that of nicotine, and in?vitro binding assays showed that cytisine possesses selective binding affinity for nAChRs, which is superior to that of nicotine and many other nAChR agonists. In vivo studies indicated that cytisine moderately increased the dopamine level in the mesolimbic system and attenuate the withdrawal symptoms.
Clinical Use
Cytisine has been used in the Eastern European countries for many years because of its proven benefits and low cost as compared with other cessation medications. A recent clinical trial in New Zealand found that at 1?month, continuous abstinence from smoking was reported for 40% of participants receiving cytisine (264 of 655) and 31% of participants receiving nicotine replacement therapy (203 of 655) . The available data indicates that cytisine is generally well-tolerated in human. However, high dosages of cytisine can be toxic.
Purification Methods
Crystallise cytisine from acetone and sublime it in a vacuum. Its solubilities are: 77% (H2O), 7.7% (Me2CO), 28.6% (EtOH), 3.3% (*C6H6), 50% (CHCl3) but it is insoluble in pet ether. The tartrate has m 206-207o [] D +45.9o, the N-tosylate has m 206-207o, and the N-acetate has m 208o. [Bohlmann et al. Angew Chem 67 708 1955, van Tamelen & Baran J Am Chem Soc 77 4944 1955, Isolation: Ing J Chem Soc 2200 1931, Govindachari et al. J Chem Soc 3839 1957, Abs config: Okuda et al. Chem Ind (London) 1751 1961, Beilstein 24 H 134, 24 I 244, 24 II 70, 24 III/IV 321.] TOXIC.
References
Husemann, Marme., Z. Chem., 161 (1865)
Husemann., ibid, 677 (1869)
Galovinsky, Goldberger, pohm., Monatsh., 80, 550 (194
CYTISINE Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| Otto Chemie Pvt. Ltd. | +91 9820041841 | Mumbai, India | 5873 | 58 | Inquiry |
| TCI Chemicals (India) Pvt. Ltd. | 1800 425 7889 | New Delhi, India | 6778 | 58 | Inquiry |
| Chengdu ChenLv Herb Co.,Ltd | +undefined13608205856 | China | 127 | 58 | Inquiry |
| Xi'an ZB Biotech Co.,Ltd | +8618591943808 | China | 816 | 58 | Inquiry |
| Hebei Guanlang Biotechnology Co,.LTD | +86-19930503253; +8619930503252 | China | 5835 | 58 | Inquiry |
| Hebei Kingfiner Technology Development Co.Ltd | +86-15532196582 +86-15373005021 | China | 2989 | 58 | Inquiry |
| Henan Fengda Chemical Co., Ltd | +86-371-86557731 +86-13613820652 | China | 20308 | 58 | Inquiry |
| BINBO BIOLOGICAL CO.,LTD | +8618629063126 | China | 346 | 58 | Inquiry |
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 | China | 21669 | 55 | Inquiry |